Science

The NIPD Genetics team has a very strong scientific publication track record in the field of in vitro genetic testing. Our scientists have published several original articles in prestigious peer-reviewed journals describing our innovative scientific work and cutting-edge technological advances.

NIPD Genetics has also presented its pioneering work at several international scientific conferences demonstrating its leadership in the field of genetic testing.

NIPD Genetics has obtained several competitive research grants for the development of novel products, showing its international competitiveness in the field of designing and development of genetic testing technologies and solutions.

George Koumbaris, Elena Kypri, Kyriakos Tsangaras, Achilleas Achilleos, Petros Mina, Maria Neofytou, et al., and Philippos C Patsalis Cell-free DNA analysis of targeted genomic regions in maternal plasma for non-invasive prenatal testing of trisomy 21, trisomy 18, trisomy 13 and fetal gender. Clinical Chemistry 62:6, 848-855, 2016

Keravnou A, Ioannides M, Loizides C, Tsangaras K, Achilleos A, Mina P, Kypri E, Hadjidaniel MD, Neofytou M, Kyriacou S, Sismani C, Koumbaris G, Patsalis PC. MeDIP combined with in-solution targeted enrichment followed by NGS: Inter-individual methylation variability of fetal-specific biomarkers and their implementation in a proof of concept study for NIPT. PLoS One. 2018 Jun 11;13(6):e0199010. doi: 10.1371/journal.pone.0199010. eCollection 2018

Neofytou MC, Tsangaras K, Kypri E, Loizides C, Ioannides M, Achilleos A, Mina P, Keravnou A, Sismani C, Koumbaris G, Patsalis PC. Targeted capture enrichment assay for non-invasive prenatal testing of large and small size sub-chromosomal deletions and duplications. PLoS One. 2017 Feb 3;12(2):e0171319. doi: 10.1371/journal.pone.0171319. eCollection 2017.

Keravnou A, Ioannides M, Tsangaras K, Loizides C, Hadjidaniel MD, Papageorgiou EA, Kyriakou S, Antoniou P, Mina P, Achilleos A, Neofytou M, Kypri E, Sismani C, Koumbaris G, Patsalis PC. Whole-genome fetal and maternal DNA methylation analysis using MeDIP-NGS for the identification of differentially methylated regions. Genet Res (Camb). 2016 Nov 11;98:e15.

Koumbaris G, Kypri E, Tsangaras K, Achilleos A, Mina P, Neofytou M, Velissariou V, Christopoulou G, Kallikas I, González-Liñán A, Benusiene E, Latos-Bielenska A, Marek P, Santana A, Nagy N, Széll M, Laudanski P, Papageorgiou EA, Ioannides M, Patsalis PC. Cell-Free DNA Analysis of Targeted Genomic Regions in Maternal Plasma for Non-Invasive Prenatal Testing of Trisomy 21, Trisomy 18, Trisomy 13, and Fetal Sex. Clin Chem. 2016 Jun;62(6):848-55. doi: 10.1373/clinchem.2015.252502.

Ioannides M, Papageorgiou EA, Keravnou A, Tsaliki E, Spyrou C, Hadjidaniel M, Sismani C, Koumbaris G, Patsalis PC. Inter-individual methylation variability in differentially methylated regions between maternal whole blood and first trimester CVS. Mol Cytogenet. 2014 Nov 1;7(1):73. doi: 10.1186/s13039-014-0073-8. eCollection 2014.

Papageorgiou EA, Koumbaris G, Kypri E, Hadjidaniel M, Patsalis PC. The Epigenome View: An Effort towards Non-Invasive Prenatal Diagnosis. Genes (Basel). 2014 Apr 9;5(2):310-29. doi: 10.3390/genes5020310.

Antoniou P, Michalokopoulos S, Ioannides M, Papageorgio EA, Patsalis PC. Identifying Differentially Methylated Regions by efficient bit-masking of DNA microarrays to use as markers for Non Invasive Prenatal Diagnosis. Engineering Intelligent Systems. 2014 Mar; 22(1).

Kyriakou S, Kypri E, Spyrou C, Tsaliki E, Velissariou V, Papageorgiou EA, Patsalis PC. Variability of ffDNA in maternal plasma does not prevent correct classification of trisomy 21 using MeDIP qPCR methodology. Prenat Diagn. 2013 Apr 25. doi: 10.1002/pd.4140.

Papageorgiou EA, Tsaliki E, Koumbaris G, Patsalis PC. Author’s response regarding “MeDIP-qPCR approach for non-invasive prenatal diagnosis of Down syndrome: accuracy and reproducibility”. Prenat Diagn. 2013 Apr;33(4):404-5. doi: 10.1002/pd.4048.

Papageorgiou EA, Patsalis PC. Maternal plasma sequencing: a powerful tool towards fetal whole genome recovery. BMC Med. 2013 Feb 27;11(1):56. doi:10.1186/1741-7015-11-56.

Patsalis PC. Technical concerns about immunoprecipitation of methylated fetal DNA for noninvasive trisomy 21 diagnosis. Nat. Med. 2012 Sep 7;18(9):1328-9. doi: 10.1038/nm.2914.

Patsalis PC, Papageorgiou EA. Non-Invasive Prenatal Diagnosis (NIPD) of Down Syndrome using real time qPCR. ECA Newsletter, July 2012.

Velissariou V, Patsalis PC. The Future of Prenatal Diagnosis of Genetic Diseases of the Embryo: Non-Invasive Prenatal Diagnosis in free DNA of the Pregnant Woman. Medical Analects, July-September 15:713-717, 2012.

Patsalis PC. A new method for non-invasive prenatal diagnosis of Down Syndrome using MeDIP real time qPCR. Applied & Translational Genomics 1 (2012) 3-8, 2012.

Tsaliki E, Papageorgiou EA, Spyrou C, Koumbaris G, Kypri E, Kyriakou S, Sotiriou C, Touvana E, Keravnou A, Karagrigoriou A, Lamnissou K, Velissariou V, Patsalis PC. MeDIP real-time qPCR of maternal peripheral blood reliably identifies trisomy 21. Prenat Diagn. 2012 Oct;32(10):996-1001 doi: 10.1002/pd.3947. [Epub 20, 12 Jul 26].

Papageorgiou EA, Patsalis PC. Non Invasive prenatal diagnosis of aneuploidies: new technologies and clinical applications. Genome Medicine. 2012 May 28;4(5):46. (Epub ahead of print).

Patsalis PC, Tsaliki E, Koumbaris G, Karagrigoriou A, Velissariou V, Papageorgiou EA. A new non-invasive prenatal diagnosis of Down syndrome through epigenetic markers and real-time qPCR. Expert Opin Biol Ther. 2012 Jun;12 Suppl 1:S155-61. Epub 2012 Apr 14.

Koumbaris G, Hatzisevastou-Loukidou H, Alexandrou A, Ioannides M, Christodoulou, C, Fitzgerald T, Rajan D, Clayton S, Kitsiou-Tzeli S, Vermeesch JR, Skordis N, Antoniou P, Kurg A, Georgiou I, Carter NP, Patsalis PC. FoSTeS, MMBIR and NAHR at the human proximal Xp region and the mechanisms of human Xq isochromosome formation. Hum Mol Genet. 2011 May 15;20(10):1925-36. Epub 2011 Feb 24.

Papageorgiou EA, Karagrigoriou A, Tsaliki E, Velissariou V, Carter NP, Patsalis PC. Fetal-specific DNA methylation ratio permits noninvasive prenatal diagnosis of trisomy 21. Nat Med. 2011 Apr;17(4):510-3. Epub 2011 Mar 6.

  • Title: “A single comprehensive NIPT for aneuploidies, microdeletions and point mutations”, 3rd Symposium on Clinical Genetics & Genomics & 19th Educational Seminar in Genetics, 31 May-1 June 2019, Athens-Greece.
  • Title: “New Advancements in NIPT for prenatal screening of genetic diseases”, The 10th International Symposium on Diabetes, Hypertension, Metabolic Syndrome and Pregnancy, 29 May – 1 June 2019, Florence-Italy.
  • Title: “New Generation Non-Invasive Genetic Testing for the Detection of Chromosomal Syndromes, Microdetion and Single Gene Diseases”, 4th Scientific Conference: "Prenatal Diagnosis and Treatment of Fetus", 18 May 2019, Athens-Greece.
  • Title: “Clinical utility of tissue and plasma DNA profiling of solid tumor cancer patients”, 2nd Conference “Genetic Innovations in 2019”, 7 February 2019, Kaunas, Lithuania.
  • Title: “Liquid Biobsy”, Annual Conference of ISMPO (India Society of Medical & Paediatric Oncology) - ISMPOCON JAIPUR 2018, 16-18 November 2018.
  • Title:’Genomics’, The omics & maternal-fetal - neonatal medicine from top research to the bed side; can we predict pregnancy complications? XXVI European Congress of the European Association of Perinatal Medicine, 5-8 September 2018, St. Petersburg, Russia.
  • Title: “cfDNA: Single gene disorders”, 17th World Congress in Fetal Medicine, 24-28 June 2018, Athens-Greece.
  • Title: “NIPT Beyond Aneuploidies”, Corporate Satellite Session during ESHG 2018 Conference, 17 June 2018, Milan-Italy.
  • “The Genome”. The 9th International Symposium on Diabetes, Hypertention, Metabolic Syndrome and Pregnancy, DIPAP2017, Barchelona, Spain, 8 March 2017, Invited Lecturer.
  • Title: “Genetics, Material Fetal Medicine and the Great Obstretrical Syndromes”. The 9th International Symposium on Diabetes, Hypertention, Metabolic Syndrome and Pregnancy, DIPAP2017, Barchelona, Spain, 8 March 2017.
  • Title: “A New Generation Non-invasive Prenatal Test for Genetics Disorders”. The First International Personalized Medicine Congress. Tehran. Iran. February 24-27, 2017.
  • Title: “Circulating Tumour DNA as a Non-invasive Biomarker in Cancer”. Genetics in Oncology, University of Kaunas, Kaunas, Lithuania. February 1-3, 2017.
  • Title: “Non Invasive Prenatal Testing of Genetic Disorders”. The 1st Asia-Pacific Symposium on Diabetes, Hypertention, Metabolic Syndrome and Pregnancy, DIPAP2016, Colombo, Sri Lanka, 8-10 September 2016.
  • Title: “Genetics Meets Fetal and Perinatal Medicine”. The 1st Asia-Pacific Symposium on Diabetes, Hypertention, Metabolic Syndrome and Pregnancy, DIPAP2016, Colombo, Sri Lanka, 8-10 September 2016.
  • Title: “Non Invasive Prenatal Diagnosis of Chromosomal Disorders”. 2nd International Conference of the Hellenic Society of Human Genetics, Athens, Greece. 4-6 November 2016, Invited Lecturer.
  • Title: “Non Invasive Prenatal Diagnosis of Genomic Disorders”. 5th International Conference of the Cyprus Society of Human Genetics, Nicosia, Cyprus. 14-15 October 2016.
  • Title: “When IVF meets NIPT: Another challenge to look at…”. Annual Meeting of the National Society of Obstetric and Gynegology, Tel Aviv, Israel. 8 March 2016.
  • Title: “Multiplex Parallel Analysis of Targeted Genomic Regions for NIPT”. Molecular Diagnostic Europe, Lisbon, Portugal. 4-7 April 2016.
  • Title: “New Generation Non-Invasive Prenatal Diagnosis with competitive advandages”, Eurogenetics Center, Thessaloniki, Greece, 25 April, 2016.
  • Title: “NIPT: Present and Future”, Two Forum – EXPO Athens, Athens, Greece.
  • Title: “Non-Invasive Prenatal Diagnosis using cffDNA”, Biomedical Center, Thessaloniki, Greece, 26 April, 2016.
  • Title: “Non-Invasive Prenatal Diagnosis using cffDNA”, University of Ioannina, Greece, 29 June, 2016.
  • Title: “Non-Invasive Prenatal Diagnosis of aneuploidies”, Biomedical Center, Athens, Greece,15 June, 2016.
  • Title: “The Veracity Test. Advances in Fetal Medicine Course. London, UK, 5-7 December 2015.
  • Title: “Development and Validation of the Veracity Non Invasive Prenatal Test., Advances in Prenatal Diagnosis. 16-19 November 2015. Boston, USA.
  • Title: “Development and Validation of the Veracity: a non-invasive prenatal test”, Vilnious University, Lithuania, 7 November, 2015.
  • Title: “Barriers and Drivers for the Implementation of Clinical Sequencing: An International Discussion Symposium”, American Society of Human Genetics Meeting, 6-10 October, 2015, Baltimore, USA. Invited Lecturer, Plenary Lecture.
  • Title: “Development and Validation of the Veracity: a newly highly accurate and cost effective non-invasive prenatal test”, Advance course in Ultrasound and Fetal Medicine, 2-4 October 2015, Belfast, UK.
  • Title: “Development and Validation of the Veracity: a non-invasive prenatal test”, Pan-Hellenic Perinatal Conference, 15-18 October 2015, Athens, Greece.
  • Title: “DNA-based Non Invasive Prenatal Diagnosis for Down Syndrome”, World Medical Summit, 7-9 July 2015, Macau, China.
  • Title: “Non Invasive Prenatal Diagnosis”, Lithuenian Academy of Science, Vilnious, Lithuenia, 16 December 2014.
  • Title: “Non Invasive Prenatal Diagnosis of Genetic Diseases”. Femmes d’ Europe, Brussels, Belgium, 16 October 2013.
  • Title: “Non Invasive Prenatal Diagnosis of Genetic Disorders”. BrainTrain EU Conference, Riken Institute, Yokahama, Japan, 19 September 2013.
  • Title: “Development of a New Non-Invasive Prenatal Diagnostic Method using Peripheral Maternal Blood Sample”. 1st Conference of the Society of Medical Geneticists, 30 May to 1 June 2013, Greece, Athens.
  • Title: “Non-Invasive Prenatal Diagnosis: From inception of the idea to the development of the product”. University of Ioannina School of Medicine, Ioannina, Greece.
  • Title: “Non Invasive prenatal diagnosis”. 11th World Congress in Fetal Medicine, 24-28 June 2012, Kos, Greece.
  • Title: “Further development and larger validation of non-invasive prenatal diagnosis for trisomy 21 using MeDIP real time qPCR”. European Society of Human Genetics 2012, 23-26 June 2012, Nurnberg, Germany.
  • Title: “Non-Invasive Prenatal Diagnosis for Trisomy 21 using MeDIP real time qPCR”. 4th Slovene Medical Genetics Symposium – New technologies and approaches in medical genetic diagnostics, 6 April 2012, Ljubljana, Slovenia.
  • Title: “Prenatal Diagnosis of Genetic Disorders: From Invasive to Non Invasive Prenatal Diagnosis”. International Down Syndrome Day, Hadassah Hospital, 22 March 2012, Jerusalem, Israel.
  • Title: “Development and Commercial Exploitation of Non-Invasive Prenatal Diagnosis”. Advanced Technologies in Medicine, Conference in Innovation, University of Crete, 25 – 26 February 2012, Greece, Cyprus.
  • Title: “Non-Invasive Prenatal Diagnosis of Down Syndrome”. 14th Conference of the Italian Society of Human Genetics (XIV SIGU), 13-16 Nov 2011, Milan, Italy.
  • Title: “Non-Invasive Prenatal Diagnosis of Down Syndrome”. 7th International Conference on Circulating Nucleic Acids in Plasma and Serum (CNAPS VII), 24-25 Oct 2011, Madrid, Spain.
  • Title: “Fetal-specific DNA methylation ratio permits non-invasive prenatal diagnosis of trisomy 21”. Cold Spring Harbor Laboratory: Personal Genomes, 30 Sept – 2 Oct 2011, New York, USA.
  • Title: “From invasive to non-invasive prenatal diagnosis”. The 5th International Conference on Birth Defects and Disabilities in the Developing World, 24-27 September 2011, Lodz, Poland.
  • Title: “Non-Invasive Prenatal Diagnosis of Down Syndrome”, Isida Clinic, 16 Sept 2011, Kiev, Ukraine.
  • Title: “Development and Validation of Non-Invasive Prenatal Diagnosis for Trisomy 21”. 8th European Cytogenetics Conference, European Cytogenetic Association, 2-5 July, 2011, Porto, Portugal.
  • Title: “Diagnosis of Aneuploides: Epigenetic Approach – Fetal-Specific DNA Methylation Ration Permits Non-Invasive Prenatal Diagnosis of Trisomy 21”. 10th Fetal Medicine World Congress, 26-30 June 2011, Malta.
  • Title: “Development and Validation of Non-Invasive Prenatal Diagnosis of Trisomy 21”. European Genetics Conference, European Society of Human Genetics, 28-31 May, 2011, Amsterdam, Netherlands.
  • Title: “Non-Invasive Prenatal Diagnosis of Down Syndrome”. University of Ioannina Medical School, 23 May, 2011, Ioannina, Greece.
  • Title: “Non-Invasive Prenatal Diagnosis of Down Syndrome”. Annual Conference of UK Clinical Molecular Genetics Society and UK Association of Clinical Cytogenetics, 4-8 April, 2011, Durham, UK.
  • Title: “Non-Invasive Prenatal Diagnosis of Down Syndrome”. MHTERA Hospital, 2-4 December 2010, Athens, Greece.

  • Title: Development of a novel, Preimplantation Genetic Testing (PGT) Kit. Competitive grant by Research Promotion Foundation, Cyprus.
  • Title: Accelerating the commercialization of non-invasive tests for liquid biopsy of solid tumor cancers (LIQ-BIOPSY). Competitive grant by Research Promotion Foundation, Cyprus.
  • Title: Proof of Concept study for ERC NIPD discovered biomarkers (mR-NIPD). Competitive grant by European Research Council (ERC) Proof of Concept Grant, European Union.
  • Title: A novel non-invasive prenatal diagnosis of genetic disorders (NIPD). Competitive grant by European Research Council (ERC) Advanced Investigator Grant, European Union.
  • Title: A new genetic laboratory for non-invasive prenatal diagnosis (ANGELAB). Competitive grant by 7th Framework Programme (ICT), European Union.
  • Title: Development and validation of a non-invasive prenatal diagnostic (NIPD) kit for aneuploidy detection (NIPD-KIT). Competitive grant by Eurostars Program, European Union and Cyprus Research Promotion Foundation.
  • Title: Development of an innovative non-invasive prenatal diagnostic test (NIPD21). Competitive grant by Ministry of Energy, Commerce, Industry and Tourism, Cyprus.
  • Title: Using fetal specific methylated markers for the development of non-invasive prenatal diagnosis for Down Syndrome. Competitive grant by Research Promotion Foundation (RPF) Young Researcher Award, Cyprus.
  • Title: Methods and compositions for non-invasive prenatal diagnosis
    of fetal aneuploidies. Competitive grant by Research Promotion Foundation Innovation, Cyprus

Latest from our Blog

Evartia_210302_1080x1080.jpg
08 Mar 2021 News

NIPD Genetics launches Evartia, a proprietary metabolic screening test that examines 223 genes involved in major metabolic pathways

March 8, 2021, Nicosia, Cyprus: NIPD Genetics announces the launch of Evartia, a new genetic test for people suspected of having inherited metabolic diseases. Evartia …

 Read More
Ventrilia_210301_1080x1080.jpg
02 Mar 2021 News

NIPD Genetics launches Ventrilia, a proprietary cardiovascular screening test of 292 genes associated with various cardiovascular syndromes and diseases

March 1, 2021, Nicosia, Cyprus: NIPD Genetics announces the launch of Ventrilia, an extensive portfolio of 8 cardiovascular genetic testing panels to detect genetic mutations …

 Read More
science_post_210217-bw.png
17 Feb 2021 News

ΠΑΡΟΥΣΙΑΣΗ ΑΠΟΤΕΛΕΣΜΑΤΩΝ ΕΡΕΥΝΑΣ ΣΧΕΤΙΚΑ ΜΕ ΤΗΝ ΓΕΝΕΤΙΚΗ ΑΝΑΛΥΣΗ ΤΩΝ ΣΤΕΛΕΧΩΝ SARS-COV-2 ΤΗΣ ΛΟΙΜΩΞΗΣ COVID-19 ΣΤΗΝ ΚΥΠΡΟ

English text follows below

Στο πλαίσιο της επιστημονικής έρευνας για την ανάλυση και την πορεία του κορωνοϊού στην Κύπρο, ο Καθηγητής Φίλιππος Πατσαλής, Γενικός Εκτελεστικός …

 Read More
Ventrilia_post.png
15 Feb 2021 Blog

HEART HEALTH AWARENESS MONTH

Heart disease is a major health issue worldwide. February was established as the month of heart health awareness in the US, UK and other countries …

 Read More
View All Posts

NIPD Genetics - Privacy Policy

General Statement

This Privacy Policy applies only to www.nipd.com and its subdomains (hereafter collectively referred to as “Sites") that link to this policy. NIPD Genetics Sites are owned by NIPD Genetics Public Company Ltd and are operated by NIPD Genetics Public Company Ltd and on occasion by a third-party that is responsible for the technical maintenance of the Sites.

If, you do not agree with this Privacy Policy, please do not access or use any of NIPD Genetics Sites.

NIPD Genetics values your interest in NIPD Genetics, its products and its services. NIPD Genetics takes the protection of your data seriously.

Personal data for purposes of this Privacy Policy, is any information by which you can be individually identified, including, but not limited to, your name, profession, address, e-mail address, and telephone number.

You may contact NIPD Genetics Public Company Ltd at
NIPD Genetics Public Company Ltd
Neas Engomis 31
Engomi, Nicosia
2409, Cyprus

NIPD Genetics Data Protection Officer can be reached at dpo@nipd.com

This Privacy Policy applies only to the Sites as defined above and which are operated by NIPD Genetics. The NIPD Genetics Privacy Policy seeks to inform the users of its Sites of the following:

NIPD Genetics will not use or share your information with anyone, except as described in this Privacy Policy. This Privacy Policy does not apply to any information we might collect by other digital and offline means and or from other digital and offline sources. The use of information collected through our Sites shall be limited to the purposes under this Privacy Policy and our Terms of Use to customers.

This page informs you of our policies regarding the collection, use, and disclosure of personal data when you use our Sites and the choices you have associated with that data.

We use your data to provide and improve the Sites. By using the Sites, you agree to the collection and use of information in accordance with this policy. Unless otherwise defined in this Privacy Policy, terms used in this Privacy Policy have the same meanings as in our Terms and Conditions, accessible from www.nipd.com

Type of personal information NIPD Genetics may collect through its Sites

Information Collection And Use

We collect several different types of information for various purposes to provide and improve our Sites and services to you.

Personal Data

While using NIPD Genetics Sites, you may be asked to provide NIPD Genetics certain personally identifiable information that can be used to contact or identify you ("Personal Information"). Personal Information that might be used to identify you includes, but is not limited to:

If you send us a query via our Contact us form, your email address, the content and any follow up emails are retained indefinitely.

Cookies and Usage Data

Usage Data

We may also collect information how the Sites are accessed and used ("Usage Data"). This Usage Data may include information such as your computer's Internet Protocol address (e.g. IP address), browser type, browser version, the pages of our Sites that you visit, the time and date of your visit, the time spent on those pages, unique device identifiers and other diagnostic data.

Tracking & Cookies Data

We use cookies and similar tracking technologies to track the activity on our Sites and hold certain information.

Cookies are files with small amount of data which may include an anonymous unique identifier. Cookies are sent to your browser from a website and stored on your device. Tracking technologies also used are beacons, tags, and scripts to collect and track information and to improve and analyze our Sites.

You can instruct your browser to refuse all cookies or to indicate when a cookie is being sent. However, if you do not accept cookies, you may not be able to use some portions of our Sites.

Examples of Cookies we use:

Session Cookies. We use Session Cookies to operate our Sites.

Preference Cookies. We use Preference Cookies to remember your preferences and various settings.

Security Cookies. We use Security Cookies for security purposes.

Visitor behavior cookies. To understand how visitors use and navigate the Sites

Keyword cookies. To understand how visitors discover the Sites.

Use of Data

www.nipd.com uses the collected data for various purposes:

Transfer of Data

Your information, including personal data, may be transferred to — and maintained on — computers located outside of your province, country or other governmental jurisdiction where the data protection laws may differ than those from your jurisdiction.

If you are located outside Cyprus and choose to provide information to us, please note that we transfer the data, including personal data, to Cyprus and process it there.

Your consent to this Privacy Policy followed by your submission of such information represents your agreement to that transfer.

www.nipd.com will take all reasonable steps necessary to ensure that your data is treated securely and in accordance with this Privacy Policy and no transfer of your personal data will take place to an organization or a country unless there are adequate controls in place including the security of your data and other personal information.

Disclosure of Data

NIPD Genetics complies with the protection of personal data regulation and will not sale or trade your personal data.

NIPD Genetics may disclose your personal data in the good faith belief that such action is necessary to:

Security of Data

The security of your data is important to us, but remember that no method of transmission over the Internet, or method of electronic storage is 100% secure. While we strive to use commercially acceptable means to protect your Personal Data, we cannot guarantee its absolute security.

Service Providers

We may employ third party companies and individuals to facilitate, maintain or operate our Sites ("Service Providers"), to provide the SItes on our behalf, to perform service-related services or to assist us in analyzing how our Sites is used.

These third parties have access to your Personal Data only to perform these tasks on our behalf and are obligated not to disclose or use it for any other purpose.

Analytics

We may use third-party Service Providers to monitor and analyze the use of our Sites.

Google Analytics

Google Analytics is a web analytics service offered by Google that tracks and reports website traffic. Google uses the data collected to track and monitor the use of our Service. This data is shared with other Google services. Google may use the collected data to contextualize and personalize the ads of its own advertising network.

You can opt-out of having made your activity on the Service available to Google Analytics by installing the Google Analytics opt-out browser add-on. The add-on prevents the Google Analytics JavaScript (ga.js, analytics.js, and dc.js) from sharing information with Google Analytics about visits activity.

For more information on the privacy practices of Google, please visit the Google Privacy & Terms web page

Access to your personal data, correction, deletion, and Opting Out

You have the right to review, update or delete any of your personal data by sending a request at NIPD Genetics Personal Data Officer pdo@nipd.com

Links to Other Sites

Our Sites may contain links to other sites that are not operated by us. If you click on a third-party link, you will be directed to that third party's site. We strongly advise you to review the Privacy Policy of every site you visit.

We have no control over and assume no responsibility for the content, privacy policies or practices of any third-party sites or services.

Children's Privacy

Our Service does not address anyone under the age of 18 ("Children").

We do not knowingly collect personally identifiable information from anyone under the age of 18. If you are a parent or guardian and you are aware that your Children has provided us with Personal Data, please contact us. If we become aware that we have collected Personal Data from children without verification of parental consent, we take steps to remove that information from our servers.

Changes to This Privacy Policy

We may update our Privacy Policy from time to time. We will notify you of any changes by posting the new Privacy Policy on this page.

We will let you know via email and/or a prominent notice on our Service, prior to the change becoming effective and update the "effective date" at the top of this Privacy Policy.

You are advised to review this Privacy Policy periodically for any changes. Changes to this Privacy Policy are effective when they are posted on this page.

Contact Us

If you have any questions about this Privacy Policy, please contact pdo@nipd.com

Ok got it!